Blog Articles

CranioSacral Therapy and Alzheimer’s Disease.

Atypical structural change in a part of the craniosacral system, called the “choroid plexus”, has been shown to contribute to Alzheimer’s disease (AD).  CranioSacral Therapy can enhance choroid plexus form, which may lead to hindering AD onset or slowing AD progression.

There are four choroid plexuses within the ventricular system.  The ventricular system is comprised of four interconnected cavities within the central part of the brain.  A choroid plexus in each ventricle produces cerebrospinal fluid (CSF).

CSF has several essential functions, such as:  protecting the brain from trauma by acting as a liquid cushion for the brain, cleansing the brain of waste and toxic substances, maintaining optimal brain pH, and supplying the brain with vital nutrients and neuro-protective substances.

One consequence of choroid plexus structural change is B-amyloid (Aβ) build up in the choroid plexuses.  CSF can pick up Aβ and carry it into the brain causing a cascade of ill effects that can eventually lead to AD.

AD is a degenerative disease of the brain triggering brain cell deterioration and brain cell death ultimately leading to symptoms, such as: dementia, anxiety, incontinence or inability to swallow.

Choroid plexus Aβ is found in people without dementia although Aβ accumulation is significantly higher in those with AD.

Why are some people more susceptible than others to harmful Aβ buildup in the choroid plexus?

One possible cause may be those with AD have either an accumulation of stressful fascial patterns, or a few significant patterns that produced choroid plexuses change.  This alteration can trigger choroid plexus cell stress leading to Aβ build up in the choroid plexuses.

A primary focus of CranioSacral Therapy (CST) is to enhance the form and function of the CSS by lessening fascial strain throughout the body and layers of fascia encasing the brain, and optimize the flow of CSF. CST can boost the flow of CSF, which has been shown to improve brain clearance of Aβ.

CST may be able to lessen fascial strain that is affecting the choroid plexuses.  This can decrease, or inhibit, the build up of Aβ.  If Aβ builds up at all then hopefully it will do so to a minimal level and AD will not develop.  Or, if Aβ has already become a problem then maybe lessening choroid plexus strain will help choroid plexus cells normalize and lessen Aβ brain burden.